Alzheimer’s Drug Discovery Foundation   Report issue

Foundation Phase 1 Phase 2 Phase 3
Founded: New York NY United States (1998)

Organization Overview

First Clinical Trial
2017
NCT03298672
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Alzheimer's Drug Discovery Foundation | Alzheimer’s Drug Discovery Foundation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 3)

Cognitive Dysfunction (Phase 1)

Psychomotor Agitation (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 9